24/7 Market News Snapshot 09 July, 2025 – MAIA Biotechnology, Inc. (NYSE:MAIA)

July 9, 2025

DENVER, Colo., 09 July, 2025 (www.247marketnews.com) – (NYSE:MAIA) are discussed in this article.
MAIA Biotechnology, Inc. is witnessing significant activity in the stock market as investor interest intensifies. The company, known for its pioneering work in targeted immunotherapies for cancer, has seen its shares rise to $2.05, an increase of 11.41% from the previous closing price of $1.84. This surge is supported by a notable trading volume of 715.30K shares, suggesting a bullish sentiment among investors. Analysts advise close monitoring of key indicators, such as moving averages and the Relative Strength Index (RSI), to gauge the sustainability of this upward momentum, while also urging caution due to possible market volatility.

Concurrently, MAIA has achieved a significant milestone in its clinical endeavors, recently announcing the successful dosing of the first patient in Taiwan for the THIO-101 Phase 2 trial, which focuses on advanced non-small cell lung cancer (NSCLC). This trial aims to evaluate the efficacy of ateganosine in heavily pre-treated NSCLC patients who have not responded to conventional treatments, including checkpoint inhibitors and chemotherapy. The trial’s design features two treatment arms, one assessing ateganosine in combination with cemiplimab (Libtayo®), and the other evaluating it as a standalone treatment. Regeneron Pharmaceuticals is collaborating with MAIA by providing Libtayo for the combination arm.

As NSCLC’s market is projected to grow from $34.1 billion in 2024 to potentially double by 2033, the THIO-101 trial represents a critical opportunity to collect vital data on ateganosine’s ability to enhance overall survival rates, which preliminary results have suggested may significantly outpace existing treatment benchmarks. Dr. Vlad Vitoc, CEO of MAIA, expresses enthusiasm for expanding the trial, highlighting the promising outcomes seen in challenging patient demographics, positioning MAIA at the forefront of oncology advancements.

Related news for (MAIA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.